

Resource Summary Report

Generated by ASWG on Aug 10, 2026

CD3 Monoclonal Antibody (UCHT1), eBioscience

RRID:AB_467059

Type: Antibody

Proper Citation

Thermo Fisher Scientific Cat# 14-0038-82, RRID:AB_467059

Antibody Information

URL: http://antibodyregistry.org/AB_467059

Proper Citation: Thermo Fisher Scientific Cat# 14-0038-82, RRID:AB_467059

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow, Functional, IHC-F, WB
Consolidation on 1/2020: AB_467059, AB_10128857

Antibody Name: CD3 Monoclonal Antibody (UCHT1), eBioscience

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone UCHT1

Antibody ID: AB_467059

Vendor: Thermo Fisher Scientific

Catalog Number: 14-0038-82

Record Creation Time: 20250820T035238+0000

Record Last Update: 20250820T172519+0000

Ratings and Alerts

No rating or validation information has been found for CD3 Monoclonal Antibody (UCHT1), eBioscience.

No alerts have been found for CD3 Monoclonal Antibody (UCHT1), eBioscience.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Chen L, et al. (2026) Tyrosine kinase 2 inhibition by GL-V9 treats psoriasiform dermatitis via macrophage-helper T-cell modulation. British journal of pharmacology.

Niu C, et al. (2025) Foxp3 confers long-term efficacy of chimeric antigen receptor-T cells via metabolic reprogramming. Cell metabolism, 37(6), 1426.

Quesada CLV, et al. (2024) Lack of inflammation or immune response in cyst tissue of patients with symptomatic non-hydrocephalic pineal cysts. Journal of the neurological sciences, 462, 123111.

Hsiao CC, et al. (2023) Osteopontin associates with brain TRM-cell transcriptome and compartmentalization in donors with and without multiple sclerosis. iScience, 26(1), 105785.

LeBlanc VG, et al. (2022) Single-cell landscapes of primary glioblastomas and matched explants and cell lines show variable retention of inter- and intratumor heterogeneity. Cancer cell, 40(4), 379.

Liu M, et al. (2022) PERK reprograms hematopoietic progenitor cells to direct tumor-promoting myelopoiesis in the spleen. The Journal of experimental medicine, 219(4).